Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Flagstar Bank NA (FLG) vs Revvity Inc (RVTY) Price & Performance

Flagstar Bank NATrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Flagstar Bank NA vs Revvity Inc — how do they compare? Flagstar Bank NA trades at $11.26 (market cap $4.71B), while Revvity Inc trades at $154.86 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 3.6× Flagstar Bank NA's market cap, and Flagstar Bank NA pays the higher dividend (0.35%). Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and Revvity Inc for 12 Days on average.

FLGRVTY
Market Cap
$4.71B$16.98B
Volume
7,410,5891,456,900
Sector
FinancialsHealth
52-Week High
$15.36$157.36
52-Week Low
$10.72$82.26
Typical Hold Time
21 Days12 Days
Enterprise Value
$15.25B$19.30B
Dividend Yield
0.35%0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Flagstar Bank NA

FLG trades at $11.21, down 0.8% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a high P/E of 378.33 but attractive P/B of 0.62, while transitioning from a $177M loss in 2025 to profitability in 2026. Recent news highlights strategic partnerships and a $250M share repurchase program, though Q2 2026 earnings missed expectations.

Analyst consensus remains bullish with a $17.07 price target (60% buy ratings), offering significant upside potential. Key risks include volatile cash flows and competitive banking pressures. The current discount to book value and institutional support suggest long-term value if profitability trends continue.

Revvity Inc

Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.

The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Flagstar Bank NA

Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.

Read more on FLG →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →